Company Profile

BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Companyâ€™s novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.

Employees

Sector

Biotechnology & Medical Research

More about the company

25-06-12	BiVictriX Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-05-27	Bivictrix Limited Announces Termination of Mrs. Susan Day Lowther as Director, Effective May 23, 2025	CI
25-05-27	BiVictriX Therapeutics plc Appoints Michael Glen Kauffman as Director, Effective May 23, 2025	CI
24-09-09	Bivictrix Therapeutics optimistic about BVX002 after in vivo testing	AN
24-09-09	BiVictriX's Ovarian Cancer Drug Conjugate Demonstrates Tumor Growth Inhibition	MT
24-08-12	Stocks rise as focus moves to economic data	AN
24-08-12	Bivictrix Therapeutics to delist as AIM offers insufficient liquidity	AN
24-08-12	AIM WINNERS & LOSERS: Global Petroleum jumps on potential Namibia deal	AN
24-08-12	BiVictriX Plans Delisting from London's AIM in September	MT
24-08-12	Bharti Global to build near 25% stake in BT	AN
24-08-01	Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Reports H1 Loss GBX-1.79	MT
24-08-01	BiVictriX Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-06-20	BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

24-09-11	BiVictriX Therapeutics plc Shares now trading on JP Jenkins	EQ
23-10-06	BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts	AQ
23-09-20	BiVictriX Therapeutics "looking really healthy" after positive first half	AQ
23-08-23	BiVictriX Therapeutics passes "exciting milestone" with US patent for BVX001	AQ
23-03-30	BiVictriX Therapeutics to "continue seeking out positive relationships"	AQ

Manager	Title	Age	Since
Tiffany Thorn CEO	Chief Executive Officer	39	2015-12-31
Adrian Howd DFI	Director of Finance/CFO	54	2023-10-02
Alison Halsall SEC	Corporate Secretary	-	2023-10-12

Director	Title	Age	Since
Tiffany Thorn BRD	Director/Board Member	39	2015-12-31
Susan Lowther BRD	Director/Board Member	67	2021-09-21
William Paris BRD	Director/Board Member	75	2021-09-21

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-09-01	Robert Hawkins	Buy	Director	20,000	0.0242%
24-09-01	Robert Hawkins	Sell	Director	20,000	0.0242%
24-08-12	Susan Lowther	Free	Director	200,000	0.2423%

BiVictriX Therapeutics plc Stock

Stocks

BVX

GB00BNXH3K91

Biotechnology & Medical Research

Latest news : BiVictriX Therapeutics plc

Press Releases: BiVictriX Therapeutics plc

Quotes and Performance

Managers and Directors: BiVictriX Therapeutics plc

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIVICTRIX THERAPEUTICS PLC	+17.65%	+33.33%	-	-	10.49M
LONZA GROUP AG	+1.68%	+3.55%	+4.86%	+10.97%	49.42B
REVOLUTION MEDICINES, INC.	+0.72%	+1.93%	+424.51%	+624.25%	40.34B
IQVIA HOLDINGS INC.	+2.54%	+2.84%	+27.06%	-3.62%	34.01B
BEONE MEDICINES AG	+0.31%	+4.16%	+23.87%	+59.76%	33.56B
CELLTRION, INC.	-2.09%	-0.80%	+3.56%	+33.56%	26.84B
ASCENDIS PHARMA A/S	-0.63%	+2.85%	-	-	17.22B
MEDPACE HOLDINGS, INC.	+0.66%	-1.48%	+66.05%	+127.36%	15.19B
IONIS PHARMACEUTICALS, INC.	-23.90%	-18.84%	+55.47%	+53.83%	13.96B
EUROFINS SCIENTIFIC SE	+2.59%	+0.50%	+15.28%	+21.25%	13.36B
Average	+2.36%	+0.83%	+77.58%	+115.92%	27.1B
Weighted average by Cap.	+0.77%	+0.90%	+93.37%	+138.87%